Please login to the form below

Not currently logged in
Email:
Password:

Major collaboration researches Alzheimer's

Boehringer Ingelheim and Vitae Pharmaceuticals have entered into a major collaboration to research and develop novel treatments for Alzheimer's disease

Boehringer Ingelheim and Vitae Pharmaceuticals have entered into a major collaboration to research and develop novel treatments for Alzheimer's disease.

The project will involve the two companies researching and developing beta-secretase (BACE) inhibitors for the treatment of Alzheimer's disease. Inhibiting BACE has the potential to slow or even stop disease progression, something that current therapies, which improve symptoms, do not do.

Under the terms of the deal, Vitae will receive $42m in upfront and near-term payments, including an equity investment in Vitae, from Boehringer Ingelheim. Additionally, Vitae will be eligible for pre-commercial milestone payments of $200m, as well as further payments based on other approved indications and/ or potential additional compounds. Boehringer Ingelheim will pay Vitae commercial performance payments and royalties on all potential future product sales.

Dr Manfred Haehl, corporate senior vice president R&D and medicine of Boehringer Ingelheim Worldwide, said: "Based on our research experience in Alzheimer's disease and our excellent experience in collaborating with Vitae for the diabetes programme, we will be using our overall expertise in CNS disease research, drug development and commercialisation to strengthen our current neuroscience portfolio."

The companies will jointly identify and advance candidates for clinical development. After which, Boehringer Ingelheim will lead development and commercialisation of all products for Alzheimer's disease. Vitae will have the right to independently develop products for certain other indications.

16th June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics